Although several HCV drugs can cure almost all infections regardless of viral genotype, picking the right drug will depend on each patient's medical history, level of liver damage, and coinfections.
VOCAL-NY has kept its doors open through the COVID-19 pandemic to serve people who use drugs and may be living with hepatitis C, but how it provides services has changed.
Retire? No, Thanks! This Doc Instead Moved to West Virginia to Fight HIV, Hepatitis C, and the Opioid Crisis
In a poor and conservative state, Judith Feinberg, M.D., aims to expand harm reduction—and bring treatment to active drug users.
Addiction needs to be addressed by prevention and treatment, but policy makers need skin in the game too.
As With HIV, New York State Was Set to Lead the Nation to End Hepatitis C. But Why Haven’t the Recommendations Been Made Public?
Activist and member of the state task force Annette Gaudino would like the public to know.
IPERGAY scientists recommended that clinicians screen patients who request PrEP, as well as patients who are already using it, for a number of key HCV risk factors.
The HIV services organization Housing Works implemented a hepatitis C treatment program in New York City, with very high completion rates.
Montreal scientists found that 88% of cannabis users had an undetectable viral load. This suggests that a very large majority of cannabis users did not have problems adhering to antiretroviral therapy.
A series of studies aim to determine whether test-and-treat strategies can be implemented for people with hepatitis C, much like programs for people living with HIV.
An in-depth update on what we know about HCV risk, symptoms, screening, outcomes, and treatment (including financial barriers).
A new study puts numbers to increasingly divergent trends in liver-related deaths vs. injection-related deaths in recent years, highlighting both the success of modern HCV treatment and the devastating effects of the opioid crisis.